India's pharmaceutical sector expects 10% revenue growth in Q1 FY27, led by strong domestic demand despite pressure in the US market. Investors may track profit margins as rising raw material and logistics costs impact profitability.
The Indian pharmaceutical industry is bracing for a divergent performance in the first quarter of fiscal year 2027. While the sector is projected to achieve a 10% year-on-year revenue increase, this headline growth masks significant differences between domestic and international segments. Analysts anticipate the domestic market will grow by 12.7%, benefiting from new product launches, the adoption of complex generic therapies, and improved productivity in medical sales forces.
US Market and Margin Challenges
In contrast to the domestic strength, the US market is expected to contract by 9.3%. This decline is largely a function of a high comparative base from the previous year, which was bolstered by significant sales of the drug Revlimid. Beyond top-line performance, investors are focusing on profitability. EBITDA margins are projected to settle around 24.6%, representing a contraction of roughly 125 basis points. This pressure on profit margins is primarily driven by elevated costs for power, logistics, and raw materials, which have become more expensive in recent quarters.
Growth in CDMO and API Segments
Contract Development and Manufacturing Organizations (CDMOs) and Active Pharmaceutical Ingredient (API) manufacturers remain a focal point for growth, with a projected 9.9% increase in revenue to ₹89 billion. This expansion is supported by a robust order book and a surge in inquiries from international pharmaceutical companies looking to diversify their manufacturing supply chains. Indian firms are increasingly investing in specialized manufacturing capabilities, such as antibody-drug conjugates and peptide production, to capture this global demand.
GLP-1 Segment Risks
While the market for GLP-1 therapies remains a major long-term opportunity, recent events highlight the operational risks involved in scaling up complex products. Dr. Reddy’s Laboratories recently paused the commercial supply of its generic semaglutide injection after detecting quality issues during the commercial scale-up process. This development serves as a reminder of the execution risks inherent in new, high-technology product segments. The ability of companies to resolve technical challenges and maintain quality standards during the transition from pilot batches to large-scale manufacturing will be a critical monitorable for the sector.
Investors will likely track the pace of recovery in the US business and whether domestic pharmaceutical companies can maintain pricing power to offset rising operational expenses. Monitoring updates on the resumption of semaglutide manufacturing and any further shifts in input costs will be essential for gauging the sector’s margin trajectory in the coming quarters.